Search company, investor...



Bridge | Alive

Total Raised




About Matrix-bio

Matrix-Bio provides cancer detection through the use of metabolomics and metabolite profiling.

Headquarters Location

1281 Win Hentschel

West Lafayette, Indiana, 47906,

United States

Missing: Matrix-bio's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Matrix-bio's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Matrix-bio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Matrix-bio is included in 2 Expert Collections, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Matrix-bio Patents

Matrix-bio has filed 7 patents.

The 3 most popular patent topics include:

  • Dosage forms
  • Drug delivery devices
  • Analgesics
patents chart

Application Date

Grant Date


Related Topics




Skin care, Extracellular matrix proteins, Cell biology, Rare diseases, Transcription factors


Application Date


Grant Date



Related Topics

Skin care, Extracellular matrix proteins, Cell biology, Rare diseases, Transcription factors



Latest Matrix-bio News

Matrix-Bio Options Metabolite Biomarker Technology From Purdue University To Evaluate Opportunities For New Cancer Diagnostic Tests

Jun 7, 2013

email Matrix-Bio Inc., a diagnostics company that uses metabolite profiling to detect cancer and other diseases, has signed an exclusive agreement with the Purdue Research Foundation optioning metabolite biomarker technology and eight patent applications to evaluate the commercial potential of cancer diagnostics tests based on the technologies. The optioned technologies include metabolite biomarkers for detecting esophageal, liver, pancreatic and colon cancer; for identifying liver cancer in patients with hepatitis C; and for predicting preoperative chemotherapy effectiveness for breast cancer treatment. Matrix-Bio's agreement is for one year with an option to extend the agreement. No other terms of the agreement were released. The new agreement builds on the existing master license agreement between Matrix-Bio and Purdue Research Foundation for breast cancer biomarkers and metabolite profiling technology developed by Dan Raftery, Matrix-Bio chief scientific officer and founder, while he was a faculty member of the Purdue University Department of Chemistry. Raftery is now director of the Northwest Metabolomics Research Center at the University of Washington in Seattle, and is also a member of the Fred Hutchinson Cancer Research Center in Seattle, one of the world's leading cancer research centers. Matrix-Bio CEO Eric Beier said the agreement will enable the company to significantly expand its pipeline of cancer detection and monitoring tests, further advancing the company's leadership in metabolomics-based cancer diagnostic technologies. "Metabolite profiling is an emerging field of diagnostics that looks at the changes in small molecule biomarkers in cells. Patterns of these metabolite biomarkers in the blood are altered when cancer is present," Beier said. "Dr. Raftery's technology identifies metabolic changes with very high sensitivity and specificity, and can detect various cancers in early, more treatable stages more accurately than currently available tests. Studies have also demonstrated that metabolite profiling can assist in monitoring cancer treatment. " The announcement comes on the heels of an exclusive global licensing and marketing agreement for metabolomic biomarkers Matrix-Bio signed with Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. Under the agreement, Quest Diagnostics has the rights to use the Matrix-Bio biomarkers for the future, potential development of a clinical lab-developed test to aid in the detection of breast cancer recurrence. Quest Diagnostics also has the option to pursue an appropriate regulatory pathway for an in vitro diagnostic version of the test. Additional terms were not disclosed. Click the stars to rate this article Matrix-Bio Options Metabolite Biomarker Technology From Purdue University To Evaluate Opportunities For New Cancer Diagnostic Tests Public / Patient

Matrix-bio Frequently Asked Questions (FAQ)

  • Where is Matrix-bio's headquarters?

    Matrix-bio's headquarters is located at 1281 Win Hentschel, West Lafayette.

  • What is Matrix-bio's latest funding round?

    Matrix-bio's latest funding round is Bridge.

  • How much did Matrix-bio raise?

    Matrix-bio raised a total of $1.11M.

  • Who are the investors of Matrix-bio?

    Investors of Matrix-bio include New Mexico Angels, Main Street Venture Fund and Emerging Innovations Fund.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.